Francesco Rogato

Francesco Rogato

Auto-generated profile, based on publicly available information

Francesco Rogato

Department of Clinical Sciences and Services, Royal Veterinary College, Hawkshead Lane, North Mymms, Hertfordshire, AL9 7TA, UK

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 August 2023 in Journal of Small Animal Practice
Verified
Journal Article
Open access
FRF. Rogato
F. Rogato
JTJ. B. Tanis
J. B. Tanis
BGB. Pons Gil
B. Pons Gil
CPC. Pittaway
C. Pittaway
CJC. A. Johnston
C. A. Johnston
AGA. Guillén
A. Guillén
Objectives: The aims of this study were to describe the clinical presentation, tumour characteristics, responses to chemotherapy protocols and toxicity in a cohort of cats with lymphoma up to 18 months of age. In addition, the probability of long‐term (>2 years) survival was explored.Materials and Methods: The medical records of client‐owned cats aged up to 18 months diagnosed with lymphoma between 2008 and 2022 at five UK‐based veterinary referral hospitals were reviewed.Results: Thirty‐three cats were included. The most common anatomical forms were mediastinal (42%), disseminated disease (30%) and renal (15%), with all cats having intermediate to large cell lymphoma. Three out of 29 cats tested were positive for FeLV but none for FIV. Twenty‐six cats were treated with multi‐agent chemotherapy protocols with complete and partial responses seen in 46% and 50% of cats, respectively. For this group, median progression‐free survival was 133 days (95% confidence interval [Cl] 67 to 199) and median survival time was 268 days (95% Cl 106 to 430). Complete response to chemotherapy was associated with a longer progression‐free survival. Seven cats were considered long‐term survivors (>2 years). Chemotherapy was generally well tolerated with none of the long‐term survivors suffering from chronic sequelae from cytotoxic treatment.Clinical Significance: Paediatric and juvenile cats with lymphoma showed a high response rate to multi‐agent chemotherapy protocols with rare significant toxicities. The presence of long‐term survivors may suggest a more favourable outcome in a subset of patients.

5 June 2025 in Veterinary and Comparative Oncology
Verified
Journal Article
Open access
AYAndrew D. Yale
Andrew D. Yale
ASAlvina So
Alvina So
AGAlexandra Guillén
Alexandra Guillén
IDIsabelle Desmas‐Bazelle
Isabelle Desmas‐Bazelle
FRFrancesco Rogato
Francesco Rogato
RJRosanne E. Jepson
Rosanne E. Jepson
Decreased kidney function is observed in some people receiving carboplatin, but limited literature explores this in dogs. The aim of this study was to evaluate the incidence and risk factors for decreased kidney function in dogs receiving carboplatin. A single‐institute retrospective cohort study compared the incidence of decreased kidney function between non‐azotaemic dogs receiving carboplatin and an age‐ and weight‐matched cancer‐bearing control group not receiving chemotherapy. Change in creatinine concentration and a linear mixed effects model were used to compare trends in creatinine between groups. Decreased kidney function was defined as a sustained increase in creatinine ≥ 26.5 μmol/L on ≥ 2 consecutive measurements compared to baseline; the VCOG‐CTCAE v2 grading system for increased creatinine was also applied. Risk factors were explored. Ninety‐eight dogs were included (n = 49/group). There was no difference in median change in creatinine concentration (+2.0 μmol/L; p = 0.311) or creatinine trends (p = 0.958) across the study period between groups. Incidence of decreased kidney function was low and did not significantly differ between groups (carboplatin group n = 4 [8.2%]; control group n = 2 [4.1%]; p = 0.678); no risk factors were identified. There was no difference in the frequency of VCOG grade one (p = 0.731), two (p = 0.641) or three (p = 0.429) creatinine adverse events between groups. Non‐azotaemic dogs receiving carboplatin do not have a significantly increased short‐term risk of decreased kidney function compared to those not receiving chemotherapy, although the numerical increase in incidence in dogs receiving carboplatin could be clinically relevant. Larger studies should aim to explore this further and investigate carboplatin's impact on subclinical and long‐term renal function.

23 July 2025 in Journal of Comparative Pathology
Verified
Journal Article
Open access
AGAlexandra Guillén
Alexandra Guillén
KKKara Kropp
Kara Kropp
FRFrancesco Rogato
Francesco Rogato
AYAndrew D. Yale
Andrew D. Yale
GHGabriella Hetesy
Gabriella Hetesy
AHAlexandros Hardas
Alexandros Hardas
In humans and cats, pancreatic carcinoma (PC) arising from the exocrine pancreas is considered an aggressive cancer associated with a poor prognosis due to its high metastatic rate. The aim of this retrospective multi-institutional study was to investigate tissue expression of biomarkers of tumour invasiveness, metastasis and immune escape in cats with PC. A secondary aim was to correlate the overall immunohistochemical scores (OISs) with histological characteristics, presence of metastasis and survival. Immunohistochemistry for COX-2, E-cadherin, CD44, c-KIT and PD-L1 was performed on 40 PC tissue samples. CD44 was expressed in all PCs with 27 (67 %) having a moderate to high OIS. PD-L1, E-cadherin, COX-2 and c-KIT expression was seen in 20 (50 %), 21 (52 %), 18 (45 %) and 14 (35 %) cases, respectively, with predominantly low OISs. Metastasis was present in 43 % of cats with a median survival time (MST) of 7 days (95 % CI 0-20; range, 1-1,094) and a 1-year survival rate of 13.8 %. When excluding cats that died or were euthanized at diagnosis, the MST was 19 days (95 % CI 0-99; range, 2-1,094). No statistical associations were found between COX-2, E-cadherin, PD-L1, CD44 or c-KIT OIS and histological subtype, necrosis, vascular invasion, mitotic count, presence of metastasis or survival. Positive E-cadherin expression was significantly associated with the presence of perineural invasion (P = 0.009; OR 1.50 [95 % CI 1.11-2.03]).

17 September 2024 in Veterinary Clinical Pathology
Verified
Journal Article
Open access
FRFrancesco Rogato
Francesco Rogato
BSBalazs Szladovits
Balazs Szladovits
HMHenny Martineau
Henny Martineau
AYAndrew D. Yale
Andrew D. Yale
JMJordan L. Mitchell
Jordan L. Mitchell
AGAlexandra Guillén
Alexandra Guillén
An eight‐year‐old male neutered crossbreed dog presented with erosive and ulcerative cutaneous lesions in the inguinal regions, the medial aspect of both thighs, and the stifles. Hematologic assessment revealed nonregenerative anemia, thrombocytopenia, and high numbers of neoplastic mononuclear cells with a variable degree of maturation. The mononuclear neoplastic cells, with nuclei measuring 10–20 microns in diameter, accounted for 57% of the nucleated blood cells. In addition, the blood contained increased numbers of mature neutrophils and monocytes with atypical morphology. Cytologic examination of the right popliteal lymph node found high numbers of large mononuclear cells with similar morphology to those in the peripheral blood. Flow cytometry of peripheral blood revealed expression by the mononuclear neoplastic cells of the pan‐leukocyte marker CD45 and myeloid markers CD14, MAC387, and myeloperoxidase (MPO). These results confirmed a diagnosis of acute myeloid leukemia (AML). Computed tomography found moderate nodular hepatosplenomegaly and multifocal bi‐cavitary lymphadenopathy. Histopathologic examination of biopsies from the cutaneous lesions identified infiltration of the dermis by intermediate to large neoplastic round cells. Further treatment was declined, and the owners elected euthanasia. Postmortem examination confirmed AML involvement in the bone marrow, peripheral and intracavitary lymph nodes, heart, liver, kidney, and skin. Neoplastic cells in the bone marrow and skin showed positive immunolabeling for ionized calcium‐binding adaptor protein 1 and MPO. To the best of our knowledge, this is the first report of ulcerative cutaneous lesions observed among the presenting clinical signs in a dog with AML and secondary leukemia cutis.